Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
22.26
-0.56 (-2.45%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
33
34
Next >
SRPT REVIEW: Sarepta Therapeutics, Inc. is Being Investigated for Securities Fraud After Elevidys Death - Investors Are Urged to Contact BFA Law
June 20, 2025
Via
ACCESS Newswire
Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand
↗
June 20, 2025
Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects.
Via
Benzinga
This Sarepta Therapeutics Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday
↗
June 20, 2025
Via
Benzinga
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
↗
June 20, 2025
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.
Via
Investor's Business Daily
Topics
Government
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
June 20, 2025
Via
ACCESS Newswire
2 Growth Stocks with All-Star Potential and 1 to Ignore
June 20, 2025
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s...
Via
StockStory
Topics
Artificial Intelligence
SRPT INQUIRY NOTICE: Lose Money on Sarepta Therapeutics, Inc.? Contact BFA Law About its Securities Fraud Investigation
June 19, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
June 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
June 18, 2025
After a second patient passed away, Sarepta Therapeutics crashed. Solid Biosciences rose over 10% in response. Wall Street sees big upside in both names.
Via
MarketBeat
Topics
Earnings
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm
June 17, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm
June 17, 2025
Via
TheNewswire.com
Topics
Fraud
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. is being Investigated for Securities Fraud after Second Elevidys Death; Investors with Losses are Notified to Contact BFA Law
June 17, 2025
From
Bleichmar Fonti & Auld LLP
Via
Business Wire
US Stock Futures Tumble After Trump Threatens 'Real End' To Iran's Nuclear Problem: '...Avoid Getting Whipsawed By Noise,' Says Expert
↗
June 17, 2025
U.S. stock futures were trading lower on Tuesday following Monday's advanced. Futures of major benchmark indices were lower in premarket.
Via
Benzinga
Topics
Government
Market Monitor News June 17 (ROKU, Advanced Micro Devices UP - Sarepta Therapeutics DOWN)
↗
June 17, 2025
Markets rebound on hopes of Iran de-escalation; oil drops, Roku surges on Amazon deal, Fed decision looms.
Via
Chartmill
Topics
Economy
Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone
↗
June 17, 2025
Via
Benzinga
Topics
Stocks
1 Oversold Stock Primed to Rebound and 2 to Steer Clear Of
June 17, 2025
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling...
Via
StockStory
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm
June 16, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm
June 16, 2025
Via
TheNewswire.com
Topics
Fraud
Monday's session: top gainers and losers
↗
June 16, 2025
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
S&P 500 Surges 1%; New York Manufacturing Activity Tumbles In June
↗
June 16, 2025
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
↗
June 16, 2025
Via
Benzinga
What the Options Market Tells Us About Sarepta Therapeutics
↗
June 16, 2025
Via
Benzinga
Why Sarepta Therapeutics (SRPT) Stock Is Down Today
June 16, 2025
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 44.4% in the afternoon session after the company reported a second death linked to its Duchenne muscular dystrophy gene therapy,....
Via
StockStory
Top movers in Monday's session
↗
June 16, 2025
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
Sarepta Therapeutics Stock Alert: Investors of Sarepta May Have Legal Claims and Are Encouraged to Contact Kehoe Law Firm, P.C. - SRPT
June 16, 2025
Via
ACCESS Newswire
These stocks are gapping in today's session
↗
June 16, 2025
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
US Stocks Higher; Dow Jumps Over 400 Points
↗
June 16, 2025
Via
Benzinga
Topics
Stocks
This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
↗
June 16, 2025
Via
Benzinga
Sarepta Therapeutics Stock Plunges On Multiple Downgrades Following Patient Death: Retail Questions ‘Crazy’ Price Targets
↗
June 16, 2025
Piper Sandler cut its Elevidys peak sales estimate to $1.7 billion from $2.4 billion.
Via
Stocktwits
Topics
Death
Sarepta Therapeutics Plummets 43% After A Second Gene Therapy Recipient Dies
↗
June 16, 2025
The company is working with an independent group to determine if there's a better immunosuppressive regimen.
Via
Investor's Business Daily
Topics
Death
Government
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
33
34
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today